Indeed, all the transplanted patients and those with lymphoproliferative syndromes responded after about 3 months of TPO-RA therapy, and among myelodysplastic patients, six out of eight achieved at least a PR. The gene discussed is TPO; the disease is lymphoproliferative syndrome.